Edward Wolin, MD, discusses the current treatment landscape of neuroendocrine tumors.
Edward Wolin, MD, senior faculty, hematologist-oncologist, and director of the Center for Carcinoid and Neuroendocrine Tumors, at Mount Sinai, discusses the current treatment landscape of neuroendocrine tumors (NETs).
NETs affect approximately 5 in every 100,000 people in the United States, Wolin says. Moreover, the incidence of NETs has risen over the past 30 years.
Currently, multiple treatment options are available for patients with NETs, including somatostatin analogs, Wolin explains.
Additionally, biologic agents, such as everolimus (Afinitor), are available, says Wolin. These systemic agents can be thought of as targeted chemotherapies.
Other options include the radiopharmaceutical Lutathera (lutetium-177 dotatate), surgical resection, interventional radiation, tumor ablation of the liver, and radioembolization of the hepatic artery, concludes Wolin.